Semaglutide

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Semaglutide

Examples of brand names: Ozempic [EU/DE]; Wegovy [EU/DE]

ATC code: A10BJ06

Main use (for orientation): Diabetes; obesity

Documented research summary

Within the documented search scope, no sufficiently attributable cannabinoid pair is established for Semaglutide. The structured assessment distinguishes documented drug context from the absence of specific interaction evidence. Missing data do not establish safety.

Uncertainties and limitations

Do not equate with subcutaneous formulations; association is not evidence of a CBD/THC interaction. Do not independently change prescribed medicines on the basis of this research dataset.

Structured assessment

Category: Drug context

Cannabinoid scope: No specifically substantiated pair involving a registered cannabinoid in the material assessed; no claim that all 28 cannabinoids were comprehensively reviewed simultaneously.

Evidence status: Drug properties supported by product information; insufficient evidence for a specific cannabinoid–drug pair effect.

Mechanism / drug context: Peptide breakdown and beta oxidation of the side chain, not conventional CYP elimination; delayed gastric emptying.

Type of supporting material: Product information and documented individual literature screening; no clinical pair trial approved for use as evidence.

Clinical interpretation: Possible changes in absorption of orally administered substances have not been quantified as a specific cannabinoid interaction.

Context: The selected US product information concerns oral tablets. Observational data on cannabis use disorder are not a pharmacokinetic pair study.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [VD_LABEL_D0256]: Original product information: drug context, not evidence for a cannabinoid–drug pair

Statement supported: Peptide breakdown and beta oxidation of the side chain, not conventional CYP elimination; delayed gastric emptying.

Source: OZEMPIC (ORAL SEMAGLUTIDE) TABLET RYBELSUS (ORAL SEMAGLUTIDE) TABLET [NOVO NORDISK PHARMACEUTICAL INDUSTRIES, LP] – DailyMed SPL [VD_LABEL_D0256]

Source role [VD_MED_38486046]: Observational association, not pharmacokinetic pair evidence

Statement supported: Cannabis use disorder as an observational endpoint; no defined CBD/THC combination study.

Source: Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study. [VD_MED_38486046]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: All individual review fields read. Original product information was rechecked only in the relevant pharmacokinetic/interaction excerpts; no complete recertification of all labels or worldwide full-text search. Literature access was based on the previously documented review; only the listed web sources were additionally read in this round. Do not equate with subcutaneous formulations; association is not evidence of a CBD/THC interaction.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[VD_LABEL_D0256] OZEMPIC (ORAL SEMAGLUTIDE) TABLET RYBELSUS (ORAL SEMAGLUTIDE) TABLET [NOVO NORDISK PHARMACEUTICAL INDUSTRIES, LP] – DailyMed SPL

Original source / bibliographic reference

Authors: Marketing authorisation holder / label provider according to the linked DailyMed product information

Year: 2026

Source type: Regulatory product information (US SPL)

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VD_MED_38486046] Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.

Original source / bibliographic reference

Authors: Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R.

Year: 2024

Source type: research-article; Journal Article; Research Support, N.I.H., Extramural

DOI: 10.1038/s41380-024-02498-5

PMID: 38486046

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility